Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Phase I/II Study of the P-Glycoprotein (Pgp) Inhibitor Zosuquidar Administered by Continuous Infusion (CIV) with Daunorubicin (DNR) and Cytarabine (ARA-C) as Primary Therapy in Older Patients with Pgp-Positive Acute Myeloid Leukemia (AML).

Jeffrey E. Lancet, MD, Jason Gotlib, MD, Meir Wetzler, MD, Selina Luger, MD, Larry D. Cripe, MD, Martin S. Tallman, MD, Ivana Gojo, MD, Deborah Mulford, MD, Maria R. Baer, MD, Alan F. List, MD, Pratik S. Multani, MD, Branimir I. Sikic, MD

Blood (2007) 110 (11): 299.

https://doi.org/10.1182/blood.V110.11.299.299

Published: 2007

Journal Articles

Differential Gene Expression Patterns and Interaction Networks in BCR/ABL Positive and Negative Adult Acute Lymphoblastic Leukemias.

Dejan Juric, Norman J. Lacayo, Meghan C. Ramsey, Janis Racevskis, Peter H. Wiernik, Jacob M. Rowe, Anthony H. Goldstone, Peter J. O’Dwyer, Elisabeth Paietta, Branimir I. Sikic

Blood (2006) 108 (11): 1836.

https://doi.org/10.1182/blood.V108.11.1836.1836

Published: 2006

Journal Articles

Gene Expression Profiling Predicts Outcome in De Novo Acute Myeloid Leukemia (AML) with Normal Karyotype: Results of Children’s Oncology Group (COG) Study POG #9421.

Norman J. Lacayo, MD, Maureen O’Brien, MD, Shweta Jain, Soheil Meshinchi, MD, PhD, Ron Yu, PhD, Dejan Juric, MD, Myron N. Chang, PhD, Robert Tibshirani, PhD, Yaddanapudi Ravindranath, MD, Howard J. Weinstein, MD, Branimir I. Sikic, MD, Gary Van Houten Dahl, MD

Blood (2006) 108 (11): 1915.

https://doi.org/10.1182/blood.V108.11.1915.1915

Published: 2006

Journal Articles

Phase I/II Pharmacodynamic Study of the P-Glycoprotein (Pgp) Inhibitor Zosuquidar Administered by Continuous Infusion (CIV) with Daunorubicin (DNR) and Cytarabine (ARA-C) as Primary Therapy in Older Patients with Acute Myeloid Leukemia (AML).

Jeffrey Lancet, Maria R. Baer, Larry D. Cripe, Alan F. List, John F. Marcelletti, Pratik S. Multani, Branimir I. Sikic

Blood (2006) 108 (11): 422.

https://doi.org/10.1182/blood.V108.11.422.422

Published: 2006

Journal Articles

Array CGH Discovers Novel Genomic Signatures in De Novo Acute Myeloid Leukemia (AML): Results of Children’s Oncology Group (COG) Study POG #9421.

Dennis J. Kuo, MD, Norman J. Lacayo, MD, Don Hoang, Dejan Juric, MD, Susana C. Raimondi, PhD, David Chen, Myron N. Chang, PhD, Yaddanapudi Ravindranath, MD, Howard J. Weinstein, MD, Branimir I. Sikic, MD, Gary Van Houten Dahl, MD

Blood (2005) 106 (11): 2771.

https://doi.org/10.1182/blood.V106.11.2771.2771

Published: 2005

Journal Articles

FLT3 Mutations Determine the Clinical Outcome in Children with De Novo Acute Myelogenous Leukemia (AML) and Normal Karyotype: Pediatric Oncology Group (POG) Study # 9421.

Norman J. Lacayo, MD, Soheil Meshinchi, MD, PhD, Susana C. Raimondi, PhD, Dennis J. Kuo, MD, Ron Yu, MA, Myron N. Chang, PhD, Cheryl L. Willman, MD, Robert Tibshirani, PhD, Yaddanapudi Ravindranath, MD, Branimir I. Sikic, MD, Howard Weinstein, MD, Gary V. Dahl, MD

Blood (2004) 104 (11): 570.

https://doi.org/10.1182/blood.V104.11.570.570

Published: 2004

Journal Articles

Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes

Norman J. Lacayo, Soheil Meshinchi, Paivi Kinnunen, Ron Yu, Yan Wang, Christianna M. Stuber, Lorrie Douglas, Romina Wahab, David L. Becton, Howard Weinstein, Myron N. Chang, Cheryl L. Willman, Jerald P. Radich, Robert Tibshirani, Yaddanapudi Ravindranath, Branimir I. Sikic, Gary V. Dahl

Blood (2004) 104 (9): 2646–2654.

https://doi.org/10.1182/blood-2003-12-4449

Published: 2004

Journal Articles

Treatment of Refractory and Relapsed Acute Myelogenous Leukemia With Combination Chemotherapy Plus the Multidrug Resistance Modulator PSC 833 (Valspodar): Presented in part at the American Society of Hematology meeting held in San Diego, CA, December 1997.

Ranjana Advani, Hussain I. Saba, Martin S. Tallman, Jacob M. Rowe, Peter H. Wiernik, Joseph Ramek, Kathleen Dugan, Bert Lum, Jenny Villena, Eric Davis, Elisabeth Paietta, Manuel Litchman, Branimir I. Sikic, Peter L. Greenberg

Blood (1999) 93 (3): 787–795.

https://doi.org/10.1182/blood.V93.3.787

Published: 1999

NARROW

Phase I/II Study of the P-Glycoprotein (Pgp) Inhibitor Zosuquidar Administered by Continuous Infusion (CIV) with Daunorubicin (DNR) and Cytarabine (ARA-C) as Primary Therapy in Older Patients with Pgp-Positive Acute Myeloid Leukemia (AML).

Differential Gene Expression Patterns and Interaction Networks in BCR/ABL Positive and Negative Adult Acute Lymphoblastic Leukemias.

Gene Expression Profiling Predicts Outcome in De Novo Acute Myeloid Leukemia (AML) with Normal Karyotype: Results of Children’s Oncology Group (COG) Study POG #9421.

Phase I/II Pharmacodynamic Study of the P-Glycoprotein (Pgp) Inhibitor Zosuquidar Administered by Continuous Infusion (CIV) with Daunorubicin (DNR) and Cytarabine (ARA-C) as Primary Therapy in Older Patients with Acute Myeloid Leukemia (AML).

Array CGH Discovers Novel Genomic Signatures in De Novo Acute Myeloid Leukemia (AML): Results of Children’s Oncology Group (COG) Study POG #9421.

FLT3 Mutations Determine the Clinical Outcome in Children with De Novo Acute Myelogenous Leukemia (AML) and Normal Karyotype: Pediatric Oncology Group (POG) Study # 9421.

Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes

Treatment of Refractory and Relapsed Acute Myelogenous Leukemia With Combination Chemotherapy Plus the Multidrug Resistance Modulator PSC 833 (Valspodar): Presented in part at the American Society of Hematology meeting held in San Diego, CA, December 1997.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only